4-carbamoylimidazolium 5-olate has been researched along with Leukemia L 1210 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukui, M; Inaba, M; Sakurai, Y; Tsukagoshi, S; Yoshida, N | 1 |
| Fukui, M; Inaba, M; Morisada, S; Nakamura, M; Ogino, S; Sakurai, Y; Tsukagoshi, S; Yoshida, N | 1 |
2 other study(ies) available for 4-carbamoylimidazolium 5-olate and Leukemia L 1210
| Article | Year |
|---|---|
Collateral sensitivity of 6-mercaptopurine-resistant sublines of P388 and L1210 leukemia to the new purine antagonists, 5-carbamoyl-1H-imidazol-4-yl piperonylate and 4-carbamoylimidazolium 5-olate.
Topics: Animals; Antineoplastic Agents; Biotransformation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Guanosine Monophosphate; Hypoxanthine Phosphoribosyltransferase; Imidazoles; Leukemia L1210; Leukemia P388; Leukemia, Experimental; Mercaptopurine; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Purines | 1982 |
Optimal treatment schedule and antitumor spectrum of 4-carbamoylimidazolium 5-olate (SM-108) in murine tumors.
Topics: Animals; Carcinoma, Ehrlich Tumor; Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation, Preclinical; Imidazoles; Leukemia L1210; Leukemia P388; Mice; Neoplasms, Experimental; Sarcoma 180 | 1983 |